Cargando…

Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway

Parkinson’s disease (PD) is a neurodegenerative movement disorder that is caused by a selective loss of dopaminergic neurons. Current PD treatments provide symptomatic relief but do not prevent or decelerate disease progression. Previous studies have suggested that acetylated and phosphorylated porp...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingjuan, Geng, Lihua, Zhang, Jingjing, Wang, Jing, Zhang, Qi, Duan, Delin, Zhang, Quanbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867626/
https://www.ncbi.nlm.nih.gov/pubmed/29509717
http://dx.doi.org/10.3390/md16030082
_version_ 1783309001886269440
author Liu, Yingjuan
Geng, Lihua
Zhang, Jingjing
Wang, Jing
Zhang, Qi
Duan, Delin
Zhang, Quanbin
author_facet Liu, Yingjuan
Geng, Lihua
Zhang, Jingjing
Wang, Jing
Zhang, Qi
Duan, Delin
Zhang, Quanbin
author_sort Liu, Yingjuan
collection PubMed
description Parkinson’s disease (PD) is a neurodegenerative movement disorder that is caused by a selective loss of dopaminergic neurons. Current PD treatments provide symptomatic relief but do not prevent or decelerate disease progression. Previous studies have suggested that acetylated and phosphorylated porphyran, derived from Porphyra, produces a neuroprotective effect against 6-OHDA-induced damage. Due to its antioxidant and neuroprotective potential, this study evaluates whether oligo-porphyran (OP) could be beneficial in an experimental model of PD in mice. The drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was intraperitoneally injected (20 mg/kg body weight) for seven days to simulate PD, followed by OP administration. We found that the behavioral deficits in spontaneous motor activity, latency to descend in a pole test, and suspension in a traction test were ameliorated, and excessive dopamine (DA) metabolism was suppressed after OP treatment. Additionally, we found that OP protected dopaminergic neurons by preventing MPTP-induced decreases in dopaminergic transporter and tyrosine hydroxylase protein levels. We speculated whether OP regulates a signaling pathway that affects the behavioral changes seen in PD mice. In this study, the PI3K/Akt/Bcl-2 pathway was detected. Our results demonstrate that OP increased the phosphorylation of PI3K/Akt/GSK-3β and inhibited the activation of caspase-3 and poly (ADP-ribose) polymerase, with changes in the Bax/Bcl-2 ratio. These results showed that OP might promote DA neuron survival in vivo by regulating the PI3K/Akt/Bcl-2 pathway, thereby ameliorating the neurobehavioral deficits in a PD mouse model and suggesting OP as a neuroprotective treatment for PD.
format Online
Article
Text
id pubmed-5867626
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-58676262018-03-27 Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway Liu, Yingjuan Geng, Lihua Zhang, Jingjing Wang, Jing Zhang, Qi Duan, Delin Zhang, Quanbin Mar Drugs Article Parkinson’s disease (PD) is a neurodegenerative movement disorder that is caused by a selective loss of dopaminergic neurons. Current PD treatments provide symptomatic relief but do not prevent or decelerate disease progression. Previous studies have suggested that acetylated and phosphorylated porphyran, derived from Porphyra, produces a neuroprotective effect against 6-OHDA-induced damage. Due to its antioxidant and neuroprotective potential, this study evaluates whether oligo-porphyran (OP) could be beneficial in an experimental model of PD in mice. The drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was intraperitoneally injected (20 mg/kg body weight) for seven days to simulate PD, followed by OP administration. We found that the behavioral deficits in spontaneous motor activity, latency to descend in a pole test, and suspension in a traction test were ameliorated, and excessive dopamine (DA) metabolism was suppressed after OP treatment. Additionally, we found that OP protected dopaminergic neurons by preventing MPTP-induced decreases in dopaminergic transporter and tyrosine hydroxylase protein levels. We speculated whether OP regulates a signaling pathway that affects the behavioral changes seen in PD mice. In this study, the PI3K/Akt/Bcl-2 pathway was detected. Our results demonstrate that OP increased the phosphorylation of PI3K/Akt/GSK-3β and inhibited the activation of caspase-3 and poly (ADP-ribose) polymerase, with changes in the Bax/Bcl-2 ratio. These results showed that OP might promote DA neuron survival in vivo by regulating the PI3K/Akt/Bcl-2 pathway, thereby ameliorating the neurobehavioral deficits in a PD mouse model and suggesting OP as a neuroprotective treatment for PD. MDPI 2018-03-06 /pmc/articles/PMC5867626/ /pubmed/29509717 http://dx.doi.org/10.3390/md16030082 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Yingjuan
Geng, Lihua
Zhang, Jingjing
Wang, Jing
Zhang, Qi
Duan, Delin
Zhang, Quanbin
Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title_full Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title_fullStr Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title_full_unstemmed Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title_short Oligo-Porphyran Ameliorates Neurobehavioral Deficits in Parkinsonian Mice by Regulating the PI3K/Akt/Bcl-2 Pathway
title_sort oligo-porphyran ameliorates neurobehavioral deficits in parkinsonian mice by regulating the pi3k/akt/bcl-2 pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867626/
https://www.ncbi.nlm.nih.gov/pubmed/29509717
http://dx.doi.org/10.3390/md16030082
work_keys_str_mv AT liuyingjuan oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT genglihua oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT zhangjingjing oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT wangjing oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT zhangqi oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT duandelin oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway
AT zhangquanbin oligoporphyranamelioratesneurobehavioraldeficitsinparkinsonianmicebyregulatingthepi3kaktbcl2pathway